A - Human Necessities – 61 – K
Patent
A - Human Necessities
61
K
A61K 31/7068 (2006.01) A61K 31/00 (2006.01) A61K 31/70 (2006.01) A61K 31/7072 (2006.01) A61K 31/7076 (2006.01) A61K 31/7084 (2006.01) A61P 1/04 (2006.01)
Patent
CA 2395108
The invention provides a method of regulating water and mucin secretions and fluid transport in the gastrointestinal tract. The invention also provides a method for treating a gastrointestinal disease in which the mucosal barrier of the gastrointestinal system is impaired. The invention additionally provides a method for correcting disorders of fluid secretion or absorption in the gastrointestinal system. The method comprises administering to a patient a pharmaceutical composition comprising a purinergic P2Y receptor agonist, in an amount effective to regulate water and mucin secretions or to correct abnormal fluid transport in the gastrointestinal tract. The pharmaceutical composition used in this invention comprises a P2Y purinergic receptor agonist such as uridine 5'-diphosphate (UDP), uridine 5'-triphosphate (UTP), cytidine 5'- diphosphate (CDP), cytidine 5'-triphosphate (CTP), adenosine 5'-diphosphate (ADP), adenosine 5'-triphosphate (ATP), and their analogs; and dinucleotide polyphosphate compounds of general Formula (IV). Said compound is prepared in an oral form, an injectable form, or a suppository form, and administered to a patient.
L'invention concerne un procédé de régulation de la sécrétion d'eau et de mucine et le transport du fluide dans le tractus gastro-intestinal. L'invention concerne également une méthode de traitement d'une maladie gastro-intestinale dans laquelle la barrière des muqueuses du système gastro-intestinal est endommagée. L'invention concerne en outre un procédé permettant de corriger les troubles de sécrétion ou d'absorption de fluide dans le système gastro-intestinal. Le procédé consiste à administrer à un patient une composition pharmaceutique renfermant un agoniste du récepteur P2Y purinergique, en quantité efficace pour réguler les sécrétions d'eau et de mucine ou pour corriger le transport anormal du fluide dans le tractus gastro-intestinal. La composition pharmaceutique utilisée renferme un agoniste du récepteur P2Y purinergique, tel que l'uridine 5'-diphosphate (UDP), l'uridine 5'-trisphosphate (UTP), la cytidine 5'-diphosphate (CDP), la cytidine 5'-triphosphate (CTP), l'adénosine 5'-diphosphate (ADP), l'adénosine 5'-triphosphate (ATP) et leurs analogues, et des composés polyphosphate dinucléotidique de formule générale (IV). Le composé est préparé sous forme orale, injectable ou de suppositoire et administré à un patient.
Cowlen Matthew
Pendergast William
Peterson Ward M.
Rideout Janet L.
Shaver Sammy R.
Gowling Lafleur Henderson Llp
Inspire Pharmaceuticals Inc.
LandOfFree
Method of treating gastrointestinal tract disease with... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method of treating gastrointestinal tract disease with..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method of treating gastrointestinal tract disease with... will most certainly appreciate the feedback.
Profile ID: LFCA-PAI-O-1779172